Sunday, March 10, 2019 10:05:39 PM
The Anavex “Iceberg” An Entire Floating Glacier?
Yes, the ability of both of the lead Anavex sigma-1 receptor agonists, Anavex 2-73 (presently) and Anavex 3-71 (in later trials) to yield positive therapeutic outcomes for a wide diversity of diseases is high. Presently, the focus is only on the three central nervous system diseases being targeted in the human clinical trials being arranged and initiated: Rett syndrome, Parkinson’s disease, and Alzheimer’s. Any sort of therapeutic success with any one of that trio will make Anavex Life Sciences Corp a profit-making concern. But a very high probability that all three will yield favorable treatment results.
It is important to understand that so many other diseases and conditions share the root pathogenic dysfunctions addressed in the new paper; poorly-functioning autophagy, allowing toxic wastes to accumulate. The Anavex molecules restore functional sigma-1 receptor activities.
As I’ve conjectured before, I’m rather certain that Missling and the other Anavex principals know full well the potentials of their molecules. It was inadvertently from that understanding that Missling made the “tip of an iceberg” comment.
I’m eager to learn what a generalized dosing regimen of either of the molecules might do to prevent or suppress many (or most?) of the debilities that accompany otherwise normal aging. In that case, Anavex would be prescribed as a prophylactic, a generalized preventative; before any actual symptoms are presented. I’m hypothesizing that the Anavex molecules will have their best effects when administered before any symptoms appear; before cellular physiologies have been grossly disrupted (the full-symptom disease state).
Anavex therapies before symptoms present. With that, how many geriatric disease states could be stopped or delayed?
Part of that might well be by the very positive outcomes of enhanced sleep patterns and durations that the Anavex molecules appear to so safely induce.
Let’s watch all of this. A big but melting iceberg (good enough)? Or, a pair of molecules of glacial size aspects?
Yes, the ability of both of the lead Anavex sigma-1 receptor agonists, Anavex 2-73 (presently) and Anavex 3-71 (in later trials) to yield positive therapeutic outcomes for a wide diversity of diseases is high. Presently, the focus is only on the three central nervous system diseases being targeted in the human clinical trials being arranged and initiated: Rett syndrome, Parkinson’s disease, and Alzheimer’s. Any sort of therapeutic success with any one of that trio will make Anavex Life Sciences Corp a profit-making concern. But a very high probability that all three will yield favorable treatment results.
It is important to understand that so many other diseases and conditions share the root pathogenic dysfunctions addressed in the new paper; poorly-functioning autophagy, allowing toxic wastes to accumulate. The Anavex molecules restore functional sigma-1 receptor activities.
As I’ve conjectured before, I’m rather certain that Missling and the other Anavex principals know full well the potentials of their molecules. It was inadvertently from that understanding that Missling made the “tip of an iceberg” comment.
I’m eager to learn what a generalized dosing regimen of either of the molecules might do to prevent or suppress many (or most?) of the debilities that accompany otherwise normal aging. In that case, Anavex would be prescribed as a prophylactic, a generalized preventative; before any actual symptoms are presented. I’m hypothesizing that the Anavex molecules will have their best effects when administered before any symptoms appear; before cellular physiologies have been grossly disrupted (the full-symptom disease state).
Anavex therapies before symptoms present. With that, how many geriatric disease states could be stopped or delayed?
Part of that might well be by the very positive outcomes of enhanced sleep patterns and durations that the Anavex molecules appear to so safely induce.
Let’s watch all of this. A big but melting iceberg (good enough)? Or, a pair of molecules of glacial size aspects?
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
